Advanced

Increasing adherence for patients with Psoriasis and Psoriatic arthritis

Norén, Annika and Aidehag, Fredrik (2015) In Diploma work IDE820 20151
Industrial Design
Abstract
This Master Thesis was made under and in collaboration with Pond Healthcare Innovation for Celgene. Celgene is a global pharmaceutical company developing treatments for cancer and other severe, immune, inflammatory conditions.
In March 2015 Celgene launched a new oral treatment called Otezla (effective substance aprimelast) on the Nordic market. With this move they entered the arena of Psoriasis and Psoratic Arthritis treatments for the first time. This oral treatment and its unique agent targets and inhibits the over-active immune system that is the cause of the disease’s symptoms. Treatments for Psoriasis (Ps) and Psoriatic Arthritis (PsA) are generally cumbersome to various degrees, and for patients with moderate to severe Psoriasis... (More)
This Master Thesis was made under and in collaboration with Pond Healthcare Innovation for Celgene. Celgene is a global pharmaceutical company developing treatments for cancer and other severe, immune, inflammatory conditions.
In March 2015 Celgene launched a new oral treatment called Otezla (effective substance aprimelast) on the Nordic market. With this move they entered the arena of Psoriasis and Psoratic Arthritis treatments for the first time. This oral treatment and its unique agent targets and inhibits the over-active immune system that is the cause of the disease’s symptoms. Treatments for Psoriasis (Ps) and Psoriatic Arthritis (PsA) are generally cumbersome to various degrees, and for patients with moderate to severe Psoriasis and Psoriatic Arthritis, Otezla offers the convenience of oral intake together with less strains on the body, compared to the alternatives available.
As Celgene wanted to differentiate themselves against other major players in this arena, they saw an opportunity in adding value for patients and healthcare providers by offering an application as treatment support.
Non-adherence, when patients don’t follow their regimen, is a common and costly problem in the healthcare world. As a result patients don’t improve their health, at all, or to the extent they could. As Ps and PsA patients as a group is at a higher risk of non-adherence due to complicated, long-term, troublesome treatments, with limited immediate effect, Celgene saw the potential benefit of an application that address this issue. But as there is no app that solves it all, we set the ambition to look beyond the app and explore further possibilities to support adherence for the patients.
Our approach and method in this project has been to design around the patient (user centred design) and to find solutions that primarily supports the patients directly or indirectly through the healthcare provider (HCP). We believe that the biggest key for creating solutions targeting adherence goes by understanding the behaviours, attitudes and influencing factors that lies behind. We have therefore done thorough research by interviewing patients
7
and HCPs, reading in on Ps and PsA forums and organization’s web pages, as well as reading articles and reports on adherence. This to truly understand what a Ps(A) diagnosed person’ s daily life looks like and how these diseases, with all its symptoms, doctors visits and heavy treatments, is affecting them. As part of the process we used the Adherence Loop as one of our tools. It is a generalized, cross-condition model that describes the role of beliefs, knowledge, and actions for designing better adherence services.
Through our interviews and research we uncovered many aspects, but what struck us the most, was how these diseases effects literally every aspect of life, physically, socially and psychologically. It has long been called ‘the healthy person’s disease’, implicitly meaning that it is ‘only cosmetic’. But even though the visual symptoms seem to be hardest to deal with, Ps and PsA is an incurable systemic disease that engages the whole body. There are many other issues around Ps(A) patients. They lead a higher risk of comorbidity (co-occurrence of other severe diseases) and for the moderate to severe cases it involves heavy treatments often with substantial side effects and strain on body.
The designed solutions presented in this report are key frames for the first version of the app, named Psapp. Future solutions within the app and solutions beyond the app is primarily presented in text with supporting images, but have not been designed at detail.
We believe that Psapp will increase adherence by:

Giving patients the tools to stay in control of their treatment without being constantly reminded of their disease.

Providing ways to track and see progression of the treatment, symptoms and goals over time.

Creating good routines in the initial phase of the treatment through reminders and user friendly information.

Enabling a clear dialogue and effective consultation with the HCP.

Motivating patients by connecting them to a bigger community, giving social support. (Less)
Please use this url to cite or link to this publication:
author
Norén, Annika and Aidehag, Fredrik
supervisor
organization
course
IDE820 20151
year
type
H2 - Master's Degree (Two Years)
subject
publication/series
Diploma work
report number
ISRN: LUT-DVIDE/ EX--15/50307—SE
ISSN
ISRN
language
English
id
7449745
date added to LUP
2015-06-25 14:44:15
date last changed
2015-06-25 14:44:15
@misc{7449745,
  abstract     = {This Master Thesis was made under and in collaboration with Pond Healthcare Innovation for Celgene. Celgene is a global pharmaceutical company developing treatments for cancer and other severe, immune, inflammatory conditions.
In March 2015 Celgene launched a new oral treatment called Otezla (effective substance aprimelast) on the Nordic market. With this move they entered the arena of Psoriasis and Psoratic Arthritis treatments for the first time. This oral treatment and its unique agent targets and inhibits the over-active immune system that is the cause of the disease’s symptoms. Treatments for Psoriasis (Ps) and Psoriatic Arthritis (PsA) are generally cumbersome to various degrees, and for patients with moderate to severe Psoriasis and Psoriatic Arthritis, Otezla offers the convenience of oral intake together with less strains on the body, compared to the alternatives available.
As Celgene wanted to differentiate themselves against other major players in this arena, they saw an opportunity in adding value for patients and healthcare providers by offering an application as treatment support.
Non-adherence, when patients don’t follow their regimen, is a common and costly problem in the healthcare world. As a result patients don’t improve their health, at all, or to the extent they could. As Ps and PsA patients as a group is at a higher risk of non-adherence due to complicated, long-term, troublesome treatments, with limited immediate effect, Celgene saw the potential benefit of an application that address this issue. But as there is no app that solves it all, we set the ambition to look beyond the app and explore further possibilities to support adherence for the patients.
Our approach and method in this project has been to design around the patient (user centred design) and to find solutions that primarily supports the patients directly or indirectly through the healthcare provider (HCP). We believe that the biggest key for creating solutions targeting adherence goes by understanding the behaviours, attitudes and influencing factors that lies behind. We have therefore done thorough research by interviewing patients
7
and HCPs, reading in on Ps and PsA forums and organization’s web pages, as well as reading articles and reports on adherence. This to truly understand what a Ps(A) diagnosed person’ s daily life looks like and how these diseases, with all its symptoms, doctors visits and heavy treatments, is affecting them. As part of the process we used the Adherence Loop as one of our tools. It is a generalized, cross-condition model that describes the role of beliefs, knowledge, and actions for designing better adherence services.
Through our interviews and research we uncovered many aspects, but what struck us the most, was how these diseases effects literally every aspect of life, physically, socially and psychologically. It has long been called ‘the healthy person’s disease’, implicitly meaning that it is ‘only cosmetic’. But even though the visual symptoms seem to be hardest to deal with, Ps and PsA is an incurable systemic disease that engages the whole body. There are many other issues around Ps(A) patients. They lead a higher risk of comorbidity (co-occurrence of other severe diseases) and for the moderate to severe cases it involves heavy treatments often with substantial side effects and strain on body.
The designed solutions presented in this report are key frames for the first version of the app, named Psapp. Future solutions within the app and solutions beyond the app is primarily presented in text with supporting images, but have not been designed at detail.
We believe that Psapp will increase adherence by:
•
Giving patients the tools to stay in control of their treatment without being constantly reminded of their disease.
•
Providing ways to track and see progression of the treatment, symptoms and goals over time.
•
Creating good routines in the initial phase of the treatment through reminders and user friendly information.
•
Enabling a clear dialogue and effective consultation with the HCP.
•
Motivating patients by connecting them to a bigger community, giving social support.},
  author       = {Norén, Annika and Aidehag, Fredrik},
  issn         = {ISRN},
  language     = {eng},
  note         = {Student Paper},
  series       = {Diploma work},
  title        = {Increasing adherence for patients with Psoriasis and Psoriatic arthritis},
  year         = {2015},
}